Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma.

Aim: To contextualize the effectiveness of tisagenlecleucel versus real-world standard of care (SoC) in relapsed/refractory follicular lymphoma. Materials & methods: A retrospective indirect matched comparison study using data from the phase II ELARA trial and the US Flatiron Health Research Database. Results: Complete response rate was 69.1 versus 17.7% and the overall response rate was 85.6 versus 58.1% in tisagenlecleucel versus SoC, post weighting by odds. For overall survival, an estimated reduction in the risk of death was observed in favor of tisagenlecleucel over SoC. The hazard ratio for progression-free survival was 0.45 (95% CI: 0.26, 0.88), and for time-to-next treatment was 0.34 (95% CI: 0.15, 0.78) with tisagenlecleucel versus SoC. Conclusion: A consistent trend toward improved efficacy end points was observed in favor of tisagenlecleucel versus SoC.

[1]  M. Dreyling,et al.  Follicular lymphoma: an update on biology and optimal therapy , 2023, Leukemia & lymphoma.

[2]  Sarah F. McGough,et al.  An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy , 2022, Blood.

[3]  Sonali M. Smith,et al.  Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma , 2022, Blood advances.

[4]  L. Sehn,et al.  Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. , 2022, The Lancet. Oncology.

[5]  Connie Kang Mosunetuzumab: First Approval , 2022, Drugs.

[6]  J. Gribben,et al.  Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma , 2022, Blood.

[7]  J. Burke Evolving third-line treatment options for follicular lymphoma. , 2022, Clinical advances in hematology & oncology : H&O.

[8]  W. Hsu,et al.  Combining the target trial and estimand frameworks to define the causal estimand: an application using real-world data to contextualize a single-arm trial , 2022, Statistics in Biopharmaceutical Research.

[9]  J. Concato,et al.  External Control Arms in Oncology: Current Use and Future Directions. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Kersten,et al.  Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial , 2021, Nature Medicine.

[11]  S. Ansell,et al.  Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma , 2021, Expert opinion on pharmacotherapy.

[12]  G. Salles,et al.  Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. , 2021, The Lancet. Oncology.

[13]  L. Sehn,et al.  Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study , 2021, Blood.

[14]  R. Advani,et al.  NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  C. Bennette,et al.  Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record‐Derived Real‐World Data , 2021, Clinical pharmacology and therapeutics.

[16]  A. Olszewski,et al.  Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma , 2021, Cancer management and research.

[17]  K. Keating,et al.  Patient-level Factors Associated With the Initial Management of Older Adults Diagnosed With Follicular Lymphoma: A Surveillance, Epidemiology, and End Results-Medicare Analysis. , 2019, Clinical lymphoma, myeloma & leukemia.

[18]  A. Freedman,et al.  Follicular lymphoma: 2020 update on diagnosis and management , 2019, American journal of hematology.

[19]  R. Dada Diagnosis and management of follicular lymphoma: A comprehensive review , 2019, European journal of haematology.

[20]  M. Hernán,et al.  The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening , 2017, European Journal of Epidemiology.

[21]  A. Rosenwald,et al.  Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. , 2016, Blood.

[22]  James M Robins,et al.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.

[23]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Angrilli,et al.  R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Kimby,et al.  ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Elizabeth A Stuart,et al.  Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.

[28]  Antonio J. Grillo-López,et al.  Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma , 2002, Expert review of anticancer therapy.

[29]  D. Rubin Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation , 2001, Health Services and Outcomes Research Methodology.

[30]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .